BioAtla (BCAB) Receivables - Net (2026)
BioAtla's (BCAB) quarterly Receivables - Net came in at $2.0 million in Q2 2026.
Powered by 
Analysis
BioAtla (BCAB) Receivables - Net (2026) Analysis & Trends
BioAtla (BCAB) has reported Receivables - Net for 1 consecutive years, with $2.0 million the latest figure, recorded in Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.24 Bn | 192.25 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.01 Bn | 176.83 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 131.33 Bn | 123.47 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.87 Bn | 73.87 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.27 Bn | 55.08 Bn | 1.37 Bn |
| 6 | Moderna | 53.93 Bn | 48.79 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.17 Bn | 29.86 Bn | 992.69 Mn |
| 8 | Biogen | 31.89 Bn | 30.60 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.12 Bn | 29.12 Bn | 1.16 Mn |
| 10 | BioAtla | 2.33 Mn | 2.33 Mn | - |